Trial Profile
Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2018
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Capecitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Aug 2006 New trial record.